Get the content you want anytime you want.
ASM Microbe 2017 Conference

Select coverage from ASM Microbe 2017 Conference is included below:

Ceftolozane-tazobactam: An Alternative Therapy to Treat <i>Pseudomonas</i> Infections
Jason Pogue, PharmD, BCPS-ID, explains the clinical significance of his research team’s findings regarding the use of ceftolozane-tazobactam to treat Pseudomonas infections.
Societal Challenges Keep At-risk Individuals from Taking PrEP
Kenneth Mayer, MD, discusses some societal challenges that at-risk individuals face today that may keep them from taking pre-exposure prophylaxis.
Why Clinicians Need to Know the Challenges Associated with Getting AST Results
ason Gallagher, PharmD, BCPS FCCP, FIDSA, explains why clinicians should be aware of the challenges associated with getting antimicrobial susceptibility testing results.
Treating <i>Pseudomonas</i>: How Does Ceftolozane-Tazobactam Differ from Other Beta-Lactams?
Jason Pogue, PharmD, BCPS-ID, explains how ceftolozane-tazobactam differs from other beta-lactams for treating Pseudomonas infections.
How to Remain Vigilant with Antimicrobial Shortages
Milena McLaughlin, PharmD, MSc, explains ways to remain vigilant when it comes to drug shortages.
Once Labeled, Always Labeled: Addressing Misconceptions About Penicillin Allergies
Elizabeth Phillips, MD, FRCPC, FRACP, addresses the misconceptions about penicillin allergies.
How Can Primary Care Providers Help Their Patients Decide if PrEP Is Right for Them?
Kenneth Mayer, MD, explains why primary care providers need to have a good sense of their patients in order to help them decide if PrEP is right for them.
Who Are the Core Partners Involved in the Fast-Track Cities Initiative?
Benjamin Young, MD, PhD, discusses the four partners behind the Fast-Track Cities Initiative.
Big advances in treatment can